{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:05:43Z","timestamp":1793577943536,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":3833,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1111\/j.1469-0691.2004.00875.x","type":"journal-article","created":{"date-parts":[[2004,7,27]],"date-time":"2004-07-27T05:08:32Z","timestamp":1090904912000},"page":"512-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Once-daily oral gatifloxacin vs. three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia"],"prefix":"10.1016","volume":"10","author":[{"given":"H.","family":"Lode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Magyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kleutgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2004.00875.x_bib1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/clinids\/18.4.501","article-title":"Community\u2010acquired pneumonia","volume":"18","author":"Marrie","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1378\/chest.105.4.1109","article-title":"Identification of low\u2010risk hospitalized patients with pneumonia: implications of early conversion to oral antimicrobial therapy","volume":"105","author":"Weingarten","year":"1994","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib3","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1001\/jama.1997.03550230056037","article-title":"Quality of care, process and outcomes in elderly patients with pneumonia","volume":"278","author":"Meehan","year":"1997","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib4","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1001\/archinte.1994.00420220085010","article-title":"Microbiology of community\u2010acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus type 1 infection","volume":"154","author":"Burack","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib5","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1055\/s-2008-1063833","article-title":"Klinik und Diagnostik der ambulant erworbenen Pneumonien","volume":"116","author":"Schaberg","year":"1991","journal-title":"Dtsch Med Wschr"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0011-5029(98)90012-8","article-title":"Community\u2010acquired pneumonia","volume":"44","author":"Cassiere","year":"1998","journal-title":"Dis Mon"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00005792-199009000-00004","article-title":"New and emerging etiologies for community\u2010acquired pneumonia with implications for therapy","volume":"69","author":"Fang","year":"1990","journal-title":"Medicine"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib8","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community\u2010acquired pneumonia","volume":"163","author":"The American Thoracic Society","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib9","first-page":"43","article-title":"Penicillin\u2010resistant pneumococci: new\u2010generation fluoroquinolones and lower respiratory tract infections","volume":"35","author":"Ramirez","year":"1999","journal-title":"Hosp Med"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community\u2010acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/40.5.639","article-title":"Comparison of the antibacterial activities of the quinolones Bay 12\u20108039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin","volume":"40","author":"Bauernfeind","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jac\/43.5.645","article-title":"Anti\u2010pneumococcal activity of gatifloxacin compared with other quinolone and non\u2010quinolone agents","volume":"43","author":"Hoellman","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0732-8893(98)00150-3","article-title":"An in vitro susceptibility study of gatifloxacin against Legionella spp","volume":"33","author":"Dubois","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1128\/AAC.41.6.1331","article-title":"In vitro and in vivo activities of AM\u20101155 against Chlamydia spp","volume":"41","author":"Miyashita","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib15","series-title":"Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA","first-page":"225","article-title":"Antimicrobial activity of gatifloxacin, a newer 8\u2010methoxy fluoroquinolone, tested against over 23 000 recent clinical isolates from the SENTRY Antimicrobial Surveillance Program, 1997 [abstract]","author":"Jones","year":"1998"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1128\/JCM.37.6.1999-2002.1999","article-title":"Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E\u2010test comparisons, and quality control guidelines for H. influenzae","volume":"37","author":"Jones","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2004.00875.x_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2165\/00003495-199958002-00045","article-title":"Antistreptococcal activity of gatifloxacin","volume":"58","author":"Jones","year":"1999","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/48.1.63","article-title":"Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre\u2010optic bronchoscopy","volume":"48","author":"Honeybourne","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1378\/chest.116.2.535","article-title":"The significance of serum vs tissue levels of antibiotics in the treatment of penicillin\u2010resistant Streptococcus pneumoniae and community\u2010acquired pneumonia. Are we looking in the wrong place?","volume":"116","author":"Siegel","year":"1999","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib20","series-title":"European guidelines for the clinical evaluation of anti\u2010infective drug products","year":"1993"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib21","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and a sample size formulae for comparative binomial trials with null hypothesis of non\u2010zero risk difference of non\u2010unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stats Med"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib22","series-title":"Nonparametric statistical methods","author":"Hollander","year":"1973"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00063198-199703000-00002","article-title":"Incidence, etiologic pathogens, and diagnostic testing of community\u2010acquired pneumonia","volume":"3","author":"File","year":"1997","journal-title":"Curr Opin Pulm Med"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0149-2918(97)80047-1","article-title":"Sparfloxacin versus cefaclor in the treatment of patients with community\u2010acquired pneumonia: a randomised, double\u2010masked, comparative, multicenter study","volume":"19","author":"Donowitz","year":"1997","journal-title":"Clin Ther"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib25","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1183\/09031936.95.08121999","article-title":"Treatment of community\u2010acquired pneumonia: a randomised comparison of sparfloxacin, amoxycillin\u2013clavulanic acid and erythromycin","volume":"8","author":"Lode","year":"1995","journal-title":"Eur Respir J"},{"issue":"suppl A","key":"10.1111\/j.1469-0691.2004.00875.x_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/37.suppl_A.83","article-title":"Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community\u2010acquired pneumonia","volume":"37","author":"Portier","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"suppl A","key":"10.1111\/j.1469-0691.2004.00875.x_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/40.suppl_1.73","article-title":"Randomized, double\u2010blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community\u2010acquired pneumonia","volume":"40","author":"O'Doherty","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib28","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","article-title":"A multicenter, randomised study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in treatment of adults with community\u2010acquired pneumonia","volume":"41","author":"File","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 11","key":"10.1111\/j.1469-0691.2004.00875.x_bib29","first-page":"S40","article-title":"Treating community\u2010acquired pneumonia with once\u2010daily gatifloxacin vs twice\u2010daily clarithromycin","volume":"20","author":"Ramirez","year":"1999","journal-title":"J Resp Dis"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib30","series-title":"Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","first-page":"421","article-title":"A randomised, double\u2010blind, multicenter comparative study of gatifloxacin (GAT) 400 mg IV and PO vs ceftriaxone + erythromycin (CTX + ERY) in treatment of community\u2010acquired pneumonia (CAP) requiring hospitalization [abstract 2241]","author":"Dowell","year":"1999"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0732-8893(02)00448-0","article-title":"Gatifloxacin used for therapy of outpatient community\u2010acquired pneumonia caused by Streptococcus pneumoniae","volume":"44","author":"Jones","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0732-8893(02)00447-9","article-title":"Oral gatifloxacin in outpatient community\u2010acquired pneumonia: results from TeqCES, a community\u2010based, open\u2010label, multicenter study","volume":"44","author":"Gotfried","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0732-8893(02)00458-3","article-title":"Gatifloxacin in community\u2010based treatment of acute respiratory tract infections in the elderly","volume":"44","author":"Nicholson","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0732-8893(02)00448-0","article-title":"Gatifloxacin used for therapy of outpatient community\u2010acquired pneumonia caused by Streptococcus pneumoniae","volume":"44","author":"Jones","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"suppl 11","key":"10.1111\/j.1469-0691.2004.00875.x_bib35","first-page":"S70","article-title":"Safety and tolerability of gatifloxacin, an advanced\u2010generation, 8\u2010methoxy fluoroquinolone","volume":"20","author":"Breen","year":"1999","journal-title":"J Resp Dis"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00002018-199513060-00004","article-title":"Tolerability of fluoroquinolone antibiotics. Past, present and future","volume":"13","author":"Ball","year":"1995","journal-title":"Drug Safety"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003495-199500492-00026","article-title":"Fluoroquinolone toxicities. An update","volume":"49","author":"Lietman","year":"1995","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib38","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2165\/00002018-199513060-00003","article-title":"A reappraisal of quinolone tolerability: the experience of their musculoskeletal effects","volume":"13","author":"Hayem","year":"1995","journal-title":"Drug Safety"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib39","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/clinids\/18.6.946","article-title":"Temafloxacin syndrome: review of 95 cases","volume":"18","author":"Blum","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00875.x_bib40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/CMR.2.4.378","article-title":"Fluoroquinolone antimicrobial agents","volume":"2","author":"Wolfson","year":"1989","journal-title":"Clin Microbiol Rev"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14623314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14623314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:15:08Z","timestamp":1761117308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14623314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S1198743X14623314"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2004.00875.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-daily oral gatifloxacin vs. three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1469-0691.2004.00875.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}